Sahajanand Medi H1FY27 Results (NSE: SMT)
Signal: Steady quarter
The read
The supplied filing does not permit a P&L trajectory read because the revenue, EBITDA, EBIT, PAT and EPS columns are not legible; the actionable disclosed development is a proposed cash investment of up to USD 7,80,000 in SNP Medical Corp., raising SMT Ireland’s stake from 14.15% to up to 17.19% by 31 March 2027.
| Metric | Value | YoY | QoQ |
|---|---|---|---|
| EBIT margin | N/A |
P&L walk
The consolidated P&L table is present in the filing but its numerical columns are not legible in the supplied text; six subsidiaries contributed revenue of ₹8,564.62 lakh in Q2FY27 and ₹14,838.02 lakh in H1FY27, with subsidiary PAT of ₹683.32 lakh in Q2 and a ₹346.24 lakh loss in H1.
Segments
The company reports a single consolidated segment, Cardiovascular Devices; within the group, six subsidiaries generated ₹8,564.62 lakh of Q2 revenue and ₹14,838.02 lakh of H1 revenue, but their H1 PAT was a ₹346.24 lakh loss despite ₹683.32 lakh of Q2 profit, indicating intra-year earnings volatility in the subsidiary base.
Key positives
- The proposed SNP Medical investment expands the product portfolio within the existing medical-device business; consideration is capped at USD 7,80,000 and the target’s 2025 revenue was USD 3,00,000.
- The group has diversified international operations across subsidiaries in Ireland, Germany, Iberia, Brazil, Switzerland, Poland, CIS, France, the US and Australia.
Key concerns
- Six subsidiaries representing ₹8,564.62 lakh of Q2 revenue and ₹14,838.02 lakh of H1 revenue were reviewed by other auditors; their reported PAT moved from ₹683.32 lakh profit in Q2 to a ₹346.24 lakh loss for H1.
- The supplied filing text does not expose the consolidated or standalone P&L numbers, preventing verification of revenue growth, margin progression, PAT quality and EPS dilution.
Research and educational content only. Not investment advice.